riccardin d

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

riccardin D: antifungal agent isolated from Dumortiera hirsute; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Dumortiera	genus	[no description available]	Dumortieraceae	[no description available]

Cross-References

ID Source	ID
PubMed CID	14132199
CHEMBL ID	1956736
MeSH ID	M0543705

Synonyms (3)

Synonym
riccardin d
CHEMBL1956736
14-oxapentacyclo[20.2.2.210,13.115,19.02,7]nonacosa-1(24),2(7),3,5,10(29),11,13(28),15,17,19(27),22,25-dodecaene-3,16,24-triol

Research Excerpts

Overview

Riccardin D is a novel macrocyclic bisbibenzyl compound extracted from Chinese liverwort plant Dumortiera hirsuta.

Excerpt	Reference	Relevance
"Riccardin D is a macrocyclic bisbibenzyl isolated from the liverwort Dumortiera hirsute in our laboratory."	( The inhibitory effect of a macrocyclic bisbibenzyl riccardin D on the biofilms of Candida albicans. Cheng, A; Lou, H; Sun, L; Wu, X, 2009)	1.33
"Riccardin D is a novel macrocyclic bisbibenzyl compound extracted from Chinese liverwort plant Dumortiera hirsuta. "	( Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma. Cheng, YN; Liu, HP; Lou, HX; Qu, XJ; Sun, CC; Xue, X; Zhang, YS; Zhao, CR, 2011)	2.05
"Riccardin D is a new compound extracted from liverwort Marchantia polymorpha L. "	( Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology. Duan, C; Jia, L; Jiao, Y; Liu, G; Liu, Y; Lou, H; Zhang, D; Zhang, Q; Zheng, D, 2012)	2.06
"Riccardin D is a macrocyclic bisbibenzyl compound extracted from liverwort plant Dumortiera hirsuta. "	( Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies. Liu, HP; Lou, HX; Qu, XJ; Sun, CC; Sun, DF; Xue, X; Yue, B; Zhao, CR, 2012)	2.14
"Riccardin D-26 is a synthesized macrocyclic bisbibenzyl compound. "	( Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human hepatocellular carcinoma growth through induction of apoptosis in p53-dependent way. Li, YY; Lou, HX; Qin, YZ; Qu, XJ; Sun, D; Wang, RQ; Xu, HM; Yuan, Y; Yue, B; Zhang, YS; Zhao, CR, 2013)	3.28
"Riccardin D (RD) is a novel compound extracted from Chinese liverwort Marchantia polymorpha L. "	( In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size. Duan, C; Guo, H; Jia, L; Jiao, Y; Li, C; Liu, G; Liu, Y; Lou, H; Shen, J; Tian, X; Zhang, D; Zhang, Q; Zheng, D, 2013)	2.11

Effects

Excerpt	Reference	Relevance
"Riccardin D has been considered as a novel DNA topo II inhibitor and potential chemotherapeutic agent for treatment of cancers."	( Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: in vitro and in vivo studies. Liu, HP; Lou, HX; Qu, XJ; Sun, CC; Sun, DF; Xue, X; Yue, B; Zhao, CR, 2012)	1.42

Treatment

Excerpt	Reference	Relevance
"Riccardin D treatment resulted in a significant inhibition of intestinal adenoma formation, showing a reduction of polyp number by 41.7%, 31.1% and 44.4%, respectively, in proximal, middle and distal portions of small intestine. "	( Inhibition of intestinal adenoma formation in APC(Min/+) mice by Riccardin D, a natural product derived from liverwort plant Dumortiera hirsuta. Cui, SX; Gao, ZH; Liu, HP; Lou, HX; Qu, XJ; Sun, DF; Wang, Y; Zhao, CR, 2012)	2.06

Bioavailability

Excerpt	Reference	Relevance
" However, the poor solubility leads to the poor bioavailability and limits its development."	( Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology. Duan, C; Jia, L; Jiao, Y; Liu, G; Liu, Y; Lou, H; Zhang, D; Zhang, Q; Zheng, D, 2012)	0.62
" The results demonstrated that Riccardin D's bioavailability was 13."	( The absorption, distribution, metabolism and excretion of Riccardin D in rats. Chen, WF; Du, FY; Li, XX; Ling, X; Lou, HX; Xing, J; Yao, H; Zan, X; Zhang, JZ, 2013)	0.92

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay ID	Title	Year	Journal	Article
AID1400965	Antiproliferative activity in human K562 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome.
AID650274	Cytotoxicity against human PC3 cells after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents.
AID1059062	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate OM481 by liquid microdilution method	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.
AID650275	Growth inhibition of human KB cells at 20 uM after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents.
AID1309043	Antibacterial activity against methicillin-sensitive Staphylococcus aureus isolate SDS15016 after 24 hrs by broth microdilution method	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	Synthesis of riccardin D derivatives as potent antimicrobial agents.
AID1059061	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate OM584 by liquid microdilution method	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.
AID1400964	Antiproliferative activity in human MCF7 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome.
AID650265	Growth inhibition of human MCF7 cells at 20 uM after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents.
AID1309045	Antifungal activity against clinical isolates of Candida albicans SC5314 after 48 hrs by broth microdilution method	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	Synthesis of riccardin D derivatives as potent antimicrobial agents.
AID1059060	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate N315 by liquid microdilution method	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.
AID1309044	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate SDSM1503 after 24 hrs by broth microdilution method	2016	Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15	Synthesis of riccardin D derivatives as potent antimicrobial agents.
AID650267	Cytotoxicity against human KB cells after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents.
AID650264	Growth inhibition of human PC3 cells at 20 uM after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents.
AID1059059	Antibacterial activity against 2-phenoxyphenol and trichlosan-resistant Staphylococcus aureus clinical isolate N315 by liquid microdilution method	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.
AID650266	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7	Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents.
AID1400963	Antiproliferative activity in human A549 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Aug-18, Volume: 136	Design, synthesis and biological evaluation of nitrogen-containing macrocyclic bisbibenzyl derivatives as potent anticancer agents by targeting the lysosome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (3.85)	29.6817
2010's	24 (92.31)	24.3611
2020's	1 (3.85)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	13.14 (24.57)
Research Supply Index	3.30 (2.92)
Research Growth Index	6.43 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (13.14)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	26 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.13	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	2.15	1	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	2.13	1	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
n-vinyl-2-pyrrolidinone N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source	2.07	1	pyrrolidin-2-ones
diphenyl diphenyl: RN given refers to unlabeled cpd; structure	2.06	1	aromatic fungicide; benzenes; biphenyls	antifungal agrochemical; antimicrobial food preservative
2-phenoxyphenol [no description available]	2.08	1	phenoxyphenol
linezolid [no description available]	2.08	1	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
doxorubicin hydrochloride [no description available]	2.15	1	anthracycline
ergosterol [no description available]	2.21	1	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; ergostanoid; phytosterols	fungal metabolite; Saccharomyces cerevisiae metabolite
stilbenes Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.	4.58	23	stilbene
marchantin c marchantin C: Antineoplastic Agents, Phytogenic from liverwort Marchantia paleacea; structure in first source	2.07	1
ceftazidime [no description available]	2.13	1	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	2.13	1	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
riccardin c riccardin C: isolated from liverworts; functions as a liver X receptor (LXR)alpha agonist and an LXRbeta antagonist; structure in first source	2.51	2
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.07	1
plagiochin e plagiochin E: reverses multidrug resistance; structure in first source	2.07	1
oxacillin sodium [no description available]	2.13	1	organic sodium salt
methylcellulose Methylcellulose: Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative.	2.07	1
retigeric acid b retigeric acid B: from a lichen, Lobaria kurokawae Yoshim; structure in first source	2.21	1
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.07	1

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	2.31	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.31	1
Breast Cancer [description not available]	2.53	2
Breast Neoplasms Tumors or cancer of the human BREAST.	2.53	2
Cancer of Colon [description not available]	2.17	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.17	1
Cancer of Prostate [description not available]	3.03	4
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	3.03	4
Osteogenic Sarcoma [description not available]	2.08	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	7.08	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.08	1
Leucocythaemia [description not available]	2.07	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	7.07	1
Cancer of Lung [description not available]	2.47	2
Angiogenesis, Pathologic [description not available]	2.47	2
Lung Neoplasms Tumors or cancer of the LUNG.	2.47	2
Carcinoma, Non-Small Cell Lung [description not available]	2.07	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.07	1
Adenoma, Basal Cell [description not available]	2.07	1
Innate Inflammatory Response [description not available]	2.07	1
Cancer of Intestines [description not available]	2.07	1
Condition, Preneoplastic [description not available]	2.07	1
Adenoma A benign epithelial tumor with a glandular organization.	7.07	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.07	1
Intestinal Neoplasms Tumors or cancer of the INTESTINES.	2.07	1
Intestinal Polyps Discrete abnormal tissue masses that protrude into the lumen of the INTESTINE. A polyp is attached to the intestinal wall either by a stalk, pedunculus, or by a broad base.	2.07	1
Precancerous Conditions Pathological conditions that tend eventually to become malignant.	2.07	1
Candida Infection [description not available]	2.07	1
Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)	2.07	1
Hepatocellular Carcinoma [description not available]	7.08	1
Cancer of Liver [description not available]	2.08	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.08	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.08	1
Carcinoma, Epidermoid [description not available]	2.08	1
Cancer of Mouth [description not available]	2.08	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.08	1
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.08	1

chemdatabank.com